.png)
.png)
Latest news from BIA
CEO Update | 16 May 2022
Last week we gave our response to the Department of Work and Pensions consultation on facilitating investments in illiquid assets. We called on the UK Government to improve transparency in the pensions industry so that pension savers have access to diversified investment strategies benefiting from the wealth-creating opportunities of the UK’s innovative, venture capital-backed industries, including biotech and life sciences, while supporting issues the public care about, like better healthcare and a cleaner environment.
CEO Update | 9 May 2022
Congratulations to Omass Therapeutics for raising $100 million in the Series B financing round, as well as two BIA member companies - Scotland-based EnteroBiotix and Solvemed group, who were featured in Forbes ‘30 under 30 Europe’ Science and Healthcare Edition for 2022. We are also glad to see engineering biology receive £20.6 million in investment from UK Research and Innovation (UKRI). Read more on IP TRIPS Waiver, update on Northern Ireland and BBSRC Business and Academia Prosperity Partnership.
Member Spotlight: Interview with Simon Chandler, Chief-Executive of Rinri Therapeutics
In light of Deaf Awareness Week, we interviewed Simon Chandler, Chief-Executive of Rinri Therapeutics, a preclinical stage biotechnology company focused on developing advanced regenerative cell therapies for hearing loss.
Guest blog: UKRI’s first five year strategy Transforming Tomorrow Together
As UK Research and Innovation (UKRI) have published their first five-year strategy transforming tomorrow together, which aims to “capture the full benefits of our research and innovation prowess” and keep the UK competitive on a global scale, Mark Kotter takes a look at what it means for bit.bio. This comes at a time we build on our record-breaking series B funding round and reflect on our role, as part of the wider biotechnology sector, in helping the UK achieve scientific superpower status.
BIA celebrates RQ BIO licencing agreement with AstraZeneca for monoclonal antibodies targeted at COVID-19
Today RQ BIO has announced a licencing agreement with AstraZeneca for its portfolio of early-stage monoclonal antibodies targeted against SARS-CoV-2, with the company also emerging from stealth mode on completion of the agreement. RQ Bio is a UK-based biotechnology company focused on developing treatments and preventative therapies based on potent broad-spectrum mAbs to address areas of unmet need in vulnerable patient populations.
Give pension savers the opportunity to invest in the development of new medicines and a greener economy
The BioIndustry Association (BIA) has called on the UK Government to improve transparency in the pensions industry so that savers can make informed decisions on what their money is invested in.
BIA response to tabled WTO TRIPS Waiver text
Steve Bates OBE, Chief Executive of the BioIndustry Association and Chair of the International Council of Biotech Associations said “Now that the text is open to public scrutiny after its formal proposal by the WTO Director-General, it is clear that what is proposed would do nothing to solve any of the challenges we face in 2022 and will only make it far harder for small companies pioneering in this space to develop future innovative solutions.
BIA reacts to NICE Antimicrobial Resistance subscription model announcement
The National Institute for Health and Care Excellence (NICE) has published draft guidance on the value of two antimicrobial drugs – Pfizer’s ceftazidime with avibactam and Shionogi’s cefiderocol – to the NHS, as part of a project to test a new subscription-style payment model for antimicrobials. NICE and its partners will now work to “review the approach taken in this project and develop routine arrangements for the evaluation and purchase of antimicrobials for the NHS.”
Coulter Partners places Chief Operating Officer at Treadwell Therapeutics, playing an integral role in the company’s evolution
Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health, and Tech, recently partnered with Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, and are pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO).
Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building
The innovation community at The Oxford Science Park, one of Europe's leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building.
Coulter Partners announces two additional appointments in Italy
Coulter Partners announces two additional appointments to its new Milan office. Giulia Bacis joins as Senior Consultant and Anna Senzacqua as Consultant. Together with Francesca Lazzarin, Executive Director, Yasemin Holland, Senior Research Associate and Giuliana Milioto, Research Associate, they make up the Italian team who will enrich the firm’s offering to companies growing from Italian headquarters and those expanding into Italy.
BioIVT to Provide Rare Biosamples for the FNIH Biomarkers Consortium Neurodegenerative Disease Project
BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration.
Here's a selection of featured BIA publications. See Resources Hub
BIA submission to the DWP consultation on facilitating investment in illiquid assets
We have responded to the Department for Work and Pensions (DWP) consultation on facilitating investment in illiquid assets.
Influencing and shaping our sector | BIA update: January to April 2022
Letter from DHSC and NHSEI on research delivery challenges in the NHS
Professor Lucy Chappell, Chief Scientific Adviser, Department of Health and Social Care (DHSC), Dr Louise Wood, DHSC Director of Science, Research and Evidence, and Dr Tim Ferris, Director of Transformation, NHS England and Improvement (NHSEI), issued a letter outlining the urgent action that must be taken to address the current research delivery challenges in the NHS.
Biotech financing update: Dec 2021 - Feb 2022
